LAUSR

available at https://pubmed.ncbi.nlm.nih.gov/32448821/ Editorial Comment: These authors aimed to investigate the effects of male hypogonadism and its treatment on oxidative stress parameters. A total of 13 male patients with hypogonadotropic hypogonadism and 20 healthy subjects were involved in the study. Patients with hypogonadism were evaluated before and after 6 months of therapy. Markers indicating lipid and protein oxidation, total oxidant status and total antioxidant capacity (TAC) were evaluated. Controls had significantly higher serum testosterone levels in comparison to hypogonadal cases before the treatment period. After the treatment of hypogonadism serum testosterone levels increased significantly. Myeloperoxidase activity, levels of advanced oxidation protein products, total lipid hydroperoxide and protein carbonyl compounds were similar between the controls and patients before treatment. Pyrolyzed protein and total oxidant status were significantly lower, and thiol levels and TAC were significantly higher in the controls vs patients with hypogonadism. Treatment of hypogonadism resulted in a significant decrease in levels of advanced oxidation protein products, while a significant increase was determined in TAC. No significant change was found in myeloperoxidase activity. These are interesting and intriguing data. Allen D. Seftel, MD Suggested Reading Zhou CK, Advani S, Chaloux M et al: Trends and patterns of testosterone therapy among U.S. male Medicare beneficiaries, 1999 to 2014. J Urol 2020; 203: 1184. Re: Controversial Aspects of Testosterone in the Regulation of Sexual Function in Late-Onset Hypogonadism M. Maggi, S. Filippi, L. Vignozzi and G. Rastrelli Endocrinology Unit, Department of Experimental, Clinical and Biomedical Sciences Mario Serio, University of Florence, Florence, Italy, Interdepartmental Laboratory of Functional and Cellular Pharmacology of Reproduction, Department of Experimental and Clinical Biomedical Sciences Mario Serio, Department of NEUROFARBA, University of Florence, Florence, Italy, and Andrology, Female Endocrinology and Gender Incongruence Unit, Department of Experimental, Clinical and Biomedical Sciences Mario Serio, University of Florence, Florence, Italy Andrology 2020; Epub ahead of print. doi: 10.1111/andr.12794 Abstract available at https://pubmed.ncbi.nlm.nih.gov/32248652/available at https://pubmed.ncbi.nlm.nih.gov/32248652/ Editorial Comment: Testosterone (T) plays a pivotal role in coordinating a series of psychological, cognitive and physical events that might (or might not) culminate in male sexual activity. Preclinical and clinical data from the authors and other laboratories and meta-analyses were used for this analysis. The authors noted that T replacement therapy is reasonable for restoring sexual drive in men with late onset hypogonadism, with some additional positive effects on erection (spontaneous and sexual related) and orgasm. In contrast, preclinical and clinical studies indicate that T administration to eugonadal subjects does not improve male sexual activity. Very interesting data. Allen D. Seftel, MD MALE AND FEMALE SEXUAL FUNCTION AND DYSFUNCTION; ANDROLOGY 1363 Copyright © 2020 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.